363 related articles for article (PubMed ID: 36980746)
1. Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Reccia I; Pai M; Kumar J; Spalding D; Frilling A
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980746
[TBL] [Abstract][Full Text] [Related]
2. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.
Kidd M; Modlin I; Öberg K
Nat Rev Clin Oncol; 2016 Nov; 13(11):691-705. PubMed ID: 27273044
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.
Fernandez CJ; Agarwal M; Pottakkat B; Haroon NN; George AS; Pappachan JM
World J Gastrointest Surg; 2021 Mar; 13(3):231-255. PubMed ID: 33796213
[TBL] [Abstract][Full Text] [Related]
4. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
5. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
Takayanagi D; Cho H; Machida E; Kawamura A; Takashima A; Wada S; Tsunoda T; Kohno T; Shiraishi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267427
[TBL] [Abstract][Full Text] [Related]
6. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
8. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression.
Zhang C; Huang Y; Long J; Yao X; Wang J; Zang S; Qu W; Wang F
Oncol Lett; 2019 Feb; 17(2):1497-1504. PubMed ID: 30675205
[TBL] [Abstract][Full Text] [Related]
9. Digital Image Analysis of Ki67 Heterogeneity Improves the Diagnosis and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms.
Zhang M; Tan C; Wang X; Ding X; Zhang B; Yang Z; Wang Y; Sheng W; Huang D
Mod Pathol; 2023 Jan; 36(1):100017. PubMed ID: 36788066
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Kaliszewski K; Ludwig M; Greniuk M; Mikuła A; Zagórski K; Rudnicki J
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454934
[TBL] [Abstract][Full Text] [Related]
11. Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism.
Santos AP; Vinagre J; Soares P; Claro I; Sanches AC; Gomes L; Fernandes I; Catarino AL; Preto J; Pereira BD; Marques AP; Rodrigues F; Amaral C; Rocha G; Mellidez JC; Simões H; Lopes JM; Bugalho MJ;
Int J Endocrinol; 2019; 2019():4518742. PubMed ID: 31467527
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data.
Rösner E; Kaemmerer D; Sänger J; Lupp A
Transl Oncol; 2022 Nov; 25():101526. PubMed ID: 36067541
[TBL] [Abstract][Full Text] [Related]
13. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
14. Role of Combined
Kaewput C; Vinjamuri S
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204371
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Dai M; Mullins CS; Lu L; Alsfasser G; Linnebacher M
World J Gastrointest Surg; 2022 May; 14(5):383-396. PubMed ID: 35734622
[TBL] [Abstract][Full Text] [Related]
16. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
Poleé IN; Hermans BCM; van der Zwan JM; Bouwense SAW; Dercksen MW; Eskens FALM; Havekes B; Hofland J; Kerkhofs TMA; Klümpen HJ; Latten-Jansen LM; Speel EM; Verburg FA; Walenkamp AME; Geurts SME; de Vos-Geelen J
Eur J Cancer; 2022 Sep; 172():252-263. PubMed ID: 35803176
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.
Pellegrino F; Granata V; Fusco R; Grassi F; Tafuto S; Perrucci L; Tralli G; Scaglione M
Tomography; 2023 Jan; 9(1):217-246. PubMed ID: 36828370
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.
Liu M; Zhang Y; Chen L; Lin Y; He Q; Zeng Y; Chen M; Chen J
Endocrine; 2021 Jan; 71(1):242-252. PubMed ID: 33010002
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Broadbent R; Wheatley R; Stajer S; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E; McNamara MG
Cancer Treat Rev; 2021 Dec; 101():102299. PubMed ID: 34662810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
